Correlated Drug Terms (1)

---

	Name (Synonyms)	Correlation
drug9	0.9% saline Wiki	1.00

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D014652	Vascular Diseases NIH	0.71

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Level of soluble P-selectin in ng/ml.

Measure: Soluble P-selectin level

Time: Day 7 after randomization

---

Secondary Outcomes

Description: Level of soluble P-selectin in ng/ml.

Measure: Soluble P-selectin level

Time: Day 14 after randomization

---

Description: Level of D-dimer in mg/L.

Measure: D-dimer level

Time: Day 7 after randomization

---

Description: Level of D-dimer in mg/L.

Measure: D-dimer level

Time: Day 14 after randomization

---

Description: Level of VWF antigen (percentage).

Measure: VWF level

Time: Day 7 after randomization

---

Description: Level of VWF antigen in (percentage).

Measure: VWF level

Time: Day 14 after randomization

---

Description: Level of C-reactive protein (CRP) in mg/dL.

Measure: CRP level

Time: Day 7 after randomization

---

Description: Level of C-reactive protein (CRP) in mg/dL.

Measure: CRP level

Time: Day 14 after randomization

---

Description: Change in the clinical status over 14 days as measured by an ordinal scale that is the first assessment of the clinical status on a given study day. The scale is as follows: 0 = Uninfected; no viral RNA detected = Ambulatory; asymptomatic; viral RNA detected = Ambulatory; symptomatic; independent = Ambulatory; symptomatic; assistance needed = Hospitalized; no oxygen therapy = Hospitalized; oxygen by mask or nasal prongs = Hospitalized; oxygen by non-invasive ventilation (NIV) or high flow = Hospitalized; intubation and mechanical ventilation, partial pressure of oxygen / fraction of inspired oxygen (pO2/FIO2) ≥ 150 or oxygen saturation / FIO2 (SpO2/FIO2) ≥ 200 = Hospitalized; intubation and mechanical ventilation, pO2/FIO2 < 150 or SpO2/FIO2 < 200 or vasopressors = Hospitalized; intubation and mechanical ventilation, pO2/FIO2 < 150 or SpO2/FIO2 < 200 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO) = Dead

Measure: Change in clinical status as assessed by the World Health Organization (WHO) Ordinal Scale for COVID-19 Trials

Time: Daily up to day 14 after randomization

---

Description: Time (days) to hospital discharge

Measure: Time to hospital discharge

Time: Up to 30 days after randomization

---

Description: Safety of crizanlizumab will by assessed by adverse events, serious adverse events, and suspected unexpected serious adverse reactions.

Measure: Safety of Crizanlizumab as assessed by adverse events

Time: Up to day 14 after randomization

---